Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,051.03 0.17 (0.02%) as of 4:30 Fri 6/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.03(B)
Last Volume: 750,617 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 46 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Goldstein Joseph L Director   –       •      –    2016-07-29 4 OE $273.67 $581,549 D/D 2,125 15,125     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2016-07-21 4 GD $0.00 $0 I/I 500,000 67,976     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2016-07-21 4 GA $0.00 $0 I/I 500,000 500,000     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-07-01 4 GD $0.00 $0 I/I 608 152,356     -
   Sanofi-Aventis 10% Owner   –       –       •   2016-06-14 4 B $361.44 $23,552,859 I/I 64,731 23,418,396 1.5     -
   Ryan Arthur F Director   –       •      –    2016-05-24 4 GD $0.00 $0 D/D 1,000 38,500     -
   Ryan Arthur F Director   –       •      –    2016-05-24 4 S $396.64 $396,640 D/D (1,000) 39,500     -
   Van Plew Daniel P EVP & General Mgr Industrial O   •       –      –    2016-05-18 4 S $385.77 $1,702,403 D/D (4,413) 1,921     -
   Van Plew Daniel P EVP & General Mgr Industrial O   •       –      –    2016-05-17 4 D $388.14 $1,958,943 D/D (5,047) 6,334     -
   Van Plew Daniel P EVP & General Mgr Industrial O   •       –      –    2016-05-17 4 OE $30.63 $289,760 D/D 9,460 11,381     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2016-05-16 4 GA $0.00 $0 I/I 4,918 2,459     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2016-05-16 4 GD $0.00 $0 I/I 4,918 0     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-05-12 4 D $368.70 $45,989,057 D/D (124,733) 438,831     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-05-12 4 OE $20.32 $4,687,499 D/D 230,684 563,564     -
   Goldstein Joseph L Director   –       •      –    2016-04-06 4 AS $425.00 $850,000 D/D (2,000) 13,000     -
   Goldstein Joseph L Director   –       •      –    2016-04-06 4 OE $177.82 $177,820 D/D 1,000 14,000     -
   Vagelos P Roy Chairman of the Board   •       •      –    2016-04-01 4 GD $0.00 $0 I/I 584 152,964     -
   Goldstein Joseph L Director   –       •      –    2016-04-01 4 AS $400.00 $800,000 D/D (2,000) 14,000     -
   Goldstein Joseph L Director   –       •      –    2016-04-01 4 OE $177.82 $355,640 D/D 2,000 16,000     -
   Goldstein Joseph L Director   –       •      –    2016-03-21 4 AS $375.00 $750,000 D/D (2,000) 14,000     -
   Goldstein Joseph L Director   –       •      –    2016-03-21 4 OE $177.82 $355,640 D/D 2,000 16,000     -
   Ryan Arthur F Director   –       •      –    2016-02-26 4 GD $0.00 $0 D/D 1,000 40,500     -
   Stahl Neil EVP Research and Development   •       –      –    2016-02-19 4 GD $0.00 $0 D/D 1,500 40,470     -
   Sanofi-Aventis   •       •       •   2016-02-17 4 B $390.14 $31,496,728 I/I 80,000 23,353,665 0.01     -
   Sanofi-Aventis   •       •       •   2016-02-16 4 B $387.43 $31,751,182 I/I 81,157 23,273,665 0.01     -
  2430 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 46 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us